NLS Pharmaceutics AG: NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
More than 100,000 deaths in the U.S. alone each year due to overdoseGlobal Opioid Use Disorder market projected to be approximately $5 Billion by 2028Mazindol classified by the U.S. Drug Enforcement Agency
United States Alex Zwyer Marianne Lambertson Trademark Office Exchange Commission European Medicines Agency
Source: finanznachrichten.de